These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 8145429)
1. [Enduracin--a nicotinic acid preparation in the treatment of hypercholesterolemia]. Kardiologiia; 1993; 33(11):67-80. PubMed ID: 8145429 [No Abstract] [Full Text] [Related]
2. [Treatment of high blood cholesterol in patients with coronary heart disease]. Nagai Y; Yanagi K; Yamashita S; Takemura K; Matsuzawa Y Nihon Rinsho; 1994 Jul; 52 Suppl(Pt 1):1088-94. PubMed ID: 12436661 [No Abstract] [Full Text] [Related]
3. What restricts the clinical use of nicotinic acid? Kei A; Liberopoulos EN; Elisaf MS Curr Vasc Pharmacol; 2011 Jul; 9(4):521-30. PubMed ID: 21314634 [TBL] [Abstract][Full Text] [Related]
4. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia. Yim BT; Chong PH Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944 [TBL] [Abstract][Full Text] [Related]
5. More on niacin: no flush, no good. Harv Health Lett; 2007 Jul; 32(9):7. PubMed ID: 17663076 [No Abstract] [Full Text] [Related]
6. Niacin extended release (ER)/simvastatin (Simcor®): a guide to its use in lipid regulation. Lyseng-Williamson KA Drugs R D; 2010; 10(4):253-60. PubMed ID: 21171671 [TBL] [Abstract][Full Text] [Related]
8. [Nicotinic acid and the derivative]. Ogaki S; Matsushima T Nihon Rinsho; 2001 Mar; 59 Suppl 3():637-41. PubMed ID: 11347146 [No Abstract] [Full Text] [Related]
9. [The use of Enduracin--a prolonged-action form of nicotinic acid--in correcting atherogenic dyslipidemias]. Oganov RG; Kiseleva NG; Aronov DM; Akhmedzhanov NM; Olfer'ev AM; Kiseleva NS; Perova NV Kardiologiia; 1993; 33(10):54-9, 6. PubMed ID: 8139175 [TBL] [Abstract][Full Text] [Related]
10. [Nicotinic acid in lipid metabolism disorders]. Ahmed K; Offermanns S Pharm Unserer Zeit; 2007; 36(2):120-5. PubMed ID: 17424997 [No Abstract] [Full Text] [Related]
11. New evidence for nicotinic acid treatment to reduce atherosclerosis. Montecucco F; Quercioli A; Dallegri F; Viviani GL; Mach F Expert Rev Cardiovasc Ther; 2010 Oct; 8(10):1457-67. PubMed ID: 20936932 [TBL] [Abstract][Full Text] [Related]
12. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials. Lukasova M; Hanson J; Tunaru S; Offermanns S Trends Pharmacol Sci; 2011 Dec; 32(12):700-7. PubMed ID: 21944259 [TBL] [Abstract][Full Text] [Related]
13. Niacin as a component of combination therapy for dyslipidemia. Miller M Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785 [TBL] [Abstract][Full Text] [Related]
14. Niacin: its value in raising HDL cholesterol is being questioned. Heart Advis; 2011 Oct; 14(10):7. PubMed ID: 23019714 [No Abstract] [Full Text] [Related]
15. Pleiotropic effects of niacin: Current possibilities for its clinical use. Zeman M; Vecka M; Perlík F; Staňková B; Hromádka R; Tvrzická E; Širc J; Hrib J; Žák A Acta Pharm; 2016 Dec; 66(4):449-469. PubMed ID: 27749252 [TBL] [Abstract][Full Text] [Related]
16. Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial. Nash MS; Lewis JE; Dyson-Hudson TA; Szlachcic Y; Yee F; Mendez AJ; Spungen AM; Bauman WA Arch Phys Med Rehabil; 2011 Mar; 92(3):399-410. PubMed ID: 21276961 [TBL] [Abstract][Full Text] [Related]
17. Nicotinic acid: an old drug with a promising future. Bodor ET; Offermanns S Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S68-75. PubMed ID: 18037924 [TBL] [Abstract][Full Text] [Related]
18. Niacin: old habits die hard. Haynes R; Rahimi K Heart; 2016 Feb; 102(3):170-1. PubMed ID: 26769376 [No Abstract] [Full Text] [Related]
19. Safety and tolerability of extended-release niacin with laropiprant. Yadav R; Kwok S; Ammori BJ; Issa B; Soran H Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050 [TBL] [Abstract][Full Text] [Related]
20. Activation of HCAR2 by niacin: benefits beyond lipid lowering. Tuteja S Pharmacogenomics; 2019 Nov; 20(16):1143-1150. PubMed ID: 31617441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]